Replies to post #97969 on Biotech Values

[DewDiligence]

MRK:

I'd definitely vote for your NVS and ABT as being #1 and #2, but I'd probably add MRK and BMY as my #3 and #4.

About a year ago, I listed some concerns about MRK in #msg-38786542. Since that post was written, MRK prevailed in the Singulair patent case but the drug—MRK’s largest by far—will still be going generic in mid 2012. The other bulleted items in #msg-38786542 still pertain for the most part, IMO.